Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
2023-505579-53-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Oct 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of tafasitamab and elranatamab in diffuse large B-cell lymphoma (DLBCL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL), follicular lymphoma (FL) and 1 more, sponsored by Incyte. Primary endpoint: Overall response rate (ORR). Planned start Oct 2022; status: authorised.
02
Drugs
tafasitamabelranatamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)follicular lymphoma (FL)composite lymphoma
Beyond the preview
Go deeper on 2023-505579-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505579-53-00.